A Study of ZN-c3 in Participants With Solid Tumors
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04158336 |
Recruitment Status :
Recruiting
First Posted : November 8, 2019
Last Update Posted : August 19, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Solid Tumor Epithelial Ovarian Cancer Fallopian Tube Cancer Peritoneal Cancer Triple Negative Breast Cancer Small Cell Lung Cancer Metastatic Breast Cancer Malignant Melanoma Non Small Cell Lung Cancer Urothelial Carcinoma | Drug: ZN-c3 | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 110 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1 Study of ZN-c3 as a Single Agent in Subjects With Solid Tumors |
Actual Study Start Date : | November 1, 2019 |
Estimated Primary Completion Date : | May 2023 |
Estimated Study Completion Date : | August 2023 |

Arm | Intervention/treatment |
---|---|
Experimental: Single Agent Dose Escalation and Expansion
Participants with solid tumors with advanced or metastatic disease who are refractory or ineligible to standard therapy(ies) or for whom no standard therapy is available.
|
Drug: ZN-c3
ZN-c3 is a study drug
Other Name: Study Drug |
- Safety and tolerability of single-agent ZN-c3, including identification of the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D), based on the incidence and severity of adverse events (AEs). [ Time Frame: Through completion, an average of 1 year ]
- Safety and tolerability of single-agent ZN-c3, including identification of the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D), based on the incidence and severity of dose-limiting toxicities (DLTs) in DLT-evaluable participants. [ Time Frame: Through Cycle 1 (each cycle is 21 days), an average of 1 year ]
- Clinical activity of WEE1 inhibition by ZN-c3 at RP2D in subjects with uterine serous carcinoma. [ Time Frame: Through completion, approximately 43 months ]Objective response rate (ORR) based on RECIST version 1.1
- Preliminary estimates of antitumor efficacy of single agent ZN-c3 [ Time Frame: Through completion, an average of 1 year ]Efficacy as defined by RECIST version 1.1

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Key Inclusion Criteria:
In order to be eligible to participate in any phase of this study, an individual must meet all of the following criteria:
- Provision of written informed consent.
- Age ≥ 18 years or the minimum legal adult age (whichever is greater) at the time of informed consent.
-
Adequate hematologic and organ function as defined by the following criteria:
- Absolute neutrophil count (ANC) ≥ 1.5 × 10^9/L; excluding measurements obtained within 7 days after daily administration of filgrastim/sargramostim or within 3 weeks after administration of pegfilgrastim.
- Platelet count ≥ 100 × 10^9/L; excluding measurements obtained within 3 days after transfusion of platelets.
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × upper limit of normal (ULN). If liver function abnormalities are due to underlying liver metastases, AST and ALT ≤ 5 x ULN.
- Total serum bilirubin ≤ 1.5 × ULN or ≤ 3 × ULN in the case of Gilbert's disease.
- Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 60 mL/min.
- Female subjects of childbearing potential must have a negative serum beta human chorionic gonadotropin test.
- Male subjects and female subjects of childbearing potential must agree to use an effective method of contraception per institutional standard prior to the first dose and for 90 days after the last dose of ZN-c3.
Individuals must meet the additional criteria in order to be eligible to participate in Phase 1:
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
- Measurable or evaluable disease per RECIST version 1.1.
Individuals must meet these additional criteria in order to be eligible to participate in Phase 2 Single Agent part of the study:
- ECOG performance status ≤ 1.
- Measurable disease per RECIST version 1.1.
Individuals must meet these additional criteria in order to be eligible to participate in Phase 2 combination with a PARP inhibitor:
- ECOG performance status ≤ 1.
- Measurable disease per RECIST version 1.1.
Individuals must meet these additional criteria in order to be eligible to participate in Phase 2 combination with a PD-1 inhibitor:
- ECOG performance status ≤ 1.
- Measurable disease per RECIST version 1.1.
Key Exclusion Criteria:
-
Any of the following treatment interventions within the specified time frame prior to Cycle 1 Day 1:
- Major surgery within 28 days.
- Radiation therapy within 21 days.
- Any prior systemic therapy regardless of the stop date, but the subject must have recovered to eligibility levels from prior toxicity.
- Autologous or allogeneic stem cell transplant within 3 months.
- Current use of an investigational agent that is not expected to be cleared by the first dosing of study drug or that has demonstrated to have prolonged side effects. Subjects should have recovered from the side effects to a Grade 0 or 1 (except alopecia).
-
A serious illness or medical condition(s) including, but not limited to, the following:
- Brain metastases that require immediate treatment or are clinically or radiologically unstable.
- Leptomeningeal disease that requires or is anticipated to require immediate treatment.
- Myocardial impairment of any cause resulting in heart failure by New York Heart Association Criteria Class III or IV.
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the Investigator would make the subject inappropriate for entry into this study.
- Significant gastrointestinal abnormalities
- Active or uncontrolled infection.
- Unresolved toxicity of Grade > 1 attributed to any prior therapies (excluding Grade 2 neuropathy, alopecia or skin pigmentation).
- Prior therapy with ZN-c3 or known hypersensitivity to any drugs similar to ZN-c3 in class.
- Subjects with active (uncontrolled, metastatic) second malignancies or requiring therapy.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04158336
Contact: Project Director | (858) 263-4333 | info@zentalis.com |
United States, Arizona | |
Site 0102 | Recruiting |
Tucson, Arizona, United States, 85719 | |
United States, Michigan | |
Site 0101 | Recruiting |
Detroit, Michigan, United States, 48201 | |
United States, Texas | |
Site 0103 | Recruiting |
Houston, Texas, United States, 77030 | |
Site 0100 | Recruiting |
San Antonio, Texas, United States, 78229 |
Responsible Party: | K-Group Beta |
ClinicalTrials.gov Identifier: | NCT04158336 |
Other Study ID Numbers: |
ZN-c3-001 |
First Posted: | November 8, 2019 Key Record Dates |
Last Update Posted: | August 19, 2021 |
Last Verified: | August 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Solid tumor |
Breast Neoplasms Lung Neoplasms Melanoma Small Cell Lung Carcinoma Triple Negative Breast Neoplasms Fallopian Tube Neoplasms Carcinoma, Ovarian Epithelial Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Respiratory Tract Neoplasms Thoracic Neoplasms Lung Diseases Respiratory Tract Diseases |
Carcinoma, Bronchogenic Bronchial Neoplasms Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms, Nerve Tissue Nevi and Melanomas Ovarian Neoplasms Endocrine Gland Neoplasms Ovarian Diseases Adnexal Diseases Genital Neoplasms, Female Urogenital Neoplasms Endocrine System Diseases |